SCHEMBL354037

SCHEMBL354037

[CH2]CC=CCC=CC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21484044 1.00 ALDH1A1 (0.31)
SCHEMBL21484043 1.00 ALDH1A1 (0.31)
SCHEMBL354036 1.00
SCHEMBL28731012 0.86
SCHEMBL8568126 0.83 TSHR (0.37)
SCHEMBL1114100 0.83
SCHEMBL8568123 0.83 TSHR (0.37)
SCHEMBL1114099 0.83
SCHEMBL8568120 0.83 TSHR (0.37)
SCHEMBL28978872 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117430538-A Thioester cationic lipids 川斯勒佰尔公司 2024-01-23 CN disclosed
CN-115768399-A Process for dyeing keratin materials comprising the use of an organosilicon compound, an alkyl (poly) glycoside, a colorant compound and a post-treatment agent 汉高股份有限及两合公司 2023-03-07 CN disclosed
US-20220016082-A1 COMBINATION THERAPIES FOR HIGH AND VERY HIGH RISK MDS MEI PHARMA, INC. 2022-01-20 US disclosed
EP-3886865-A1 COMBINATION THERAPIES FOR HIGH AND VERY HIGH RISK MDS MEI Pharma, Inc. (US) 2021-10-06 EP disclosed
US-20210100775-A1 COMBINATION THERAPIES MEI PHARMA, INC. 2021-04-08 US disclosed
EP-3662911-A1 COMBINATION OF AZACITIDINE AND PRACINOSTAT TO TREAT MYELODYSPLASTIC SYNDROME (MDS) MEI Pharma, Inc. (US) 2020-06-10 EP disclosed
WO-2020112848-A1 COMBINATION THERAPIES FOR HIGH AND VERY HIGH RISK MDS MEI PHARMA, INC. (US) 2020-06-04 WO disclosed
EP-2914254-B1 COMBINATION THERAPIES TO TREAT CHEMORESISTANT CANCERS MEI PHARMA INC (US) 2020-01-08 EP disclosed
CN-107074757-B The manufacturing method of trifluoromethyl alkylthio chemical combination object 组合化学工业株式会社 2019-05-03 CN disclosed
EP-2131840-B1 COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT MEI PHARMA INC (US) 2018-10-17 EP disclosed
US-6683183-B2 BICYCLIC HETEROCYCLES THAT INHIBIT CYCLIN-DEPENDENT KINASE OR TYROSINE KINASE ENZYMES, OR BOTH, FOR TREATMENT OF PROLIFERATIVE DISORDERS WARNER-LAMBERT COMPANY 2004-01-27 US disclosed
US-20030113533-A1 Double sided adhesive tape TESA SE (DE) 2003-06-19 US disclosed
US-20020061865-A1 Pyridotriazines and pyridopyridazines KRAMER JAMES BERNARD (US) 2002-05-23 US disclosed
EP-1195378-A1 Pyridotriazines and pyridopyridazines WARNER-LAMBERT COMPANY (US) 2002-04-10 EP disclosed
EP-1080092-A2 BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION WARNER-LAMBERT COMPANY (US) 2001-03-07 EP disclosed
WO-1999061444-A2 BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION WARNER-LAMBERT COMPANY (US) 1999-12-02 WO disclosed
WO-1997026873-A1 ANTIMICROBIAL AURONE DERIVATIVES PHYTERA, INC. (US) 1997-07-31 WO disclosed
US-5597854-A PHOTOGRAPHIC APPLICATIONS, COATINGS, BINDERS, POLYMERS, TRIAZINE OR PYRIMIDINE COMPOUNDS CIBA-GEIGY CORPORATION (US) 1997-01-28 US disclosed
EP-0039913-B1 TETRAZOLYLCOUMARIN DERIVATIVES, PROCESS FOR PREPARING THE SAME AND COMPOSITION CONTAINING THE SAME Kaken Pharmaceutical Co., Ltd. (JP) 1985-01-23 EP disclosed
EP-0021637-A1 Amidothiol derivatives NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1981-01-07 EP disclosed